First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.

被引：17

作者：

Flinn, Ian

van der Jagt, Richard

Chang, Julie E.

Wood, Peter

Hawkins, Tim E.

MacDonald, David

Trotman, Judith

Simpson, David

Kolibaba, Kathryn S.

Issa, Samar

Hallman, Doreen M.

Chen, Ling

Burke, John M.

机构：

[1] Tennessee Onc, Nashville, TN USA

[2] Ottawa Hosp, Ottawa, ON, Canada

[3] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA

[4] Princess Alexandra Hosp, Woolloongabba, Qld, Australia

[5] Auckland City Hosp, Auckland, New Zealand

[6] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[7] Concord Repatriat Gen Hosp, Concord, NSW, Australia

[8] North Shore Hosp, Auckland, New Zealand

[9] US Oncol Res, The Woodlands, TX USA

[10] Middlemore Hosp, Auckland, New Zealand

[11] Teva Global Clin Operat, Malvern, PA USA

[12] Teva Biometr Operat, Malvern, PA USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.7500

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7500

引用

页数：6